What is Galectin Therapeutics Inc.'s earnings per share (EPS)?

Galectin Therapeutics Inc. (GALT) reported diluted earnings per share of -$0.48 for fiscal year 2025. This represents a 36.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Galectin Therapeutics Inc. (GALT) Financials

GALT

FY2025 annual

Revenue Not reported for FY2025

Net Income -$30.8M +34.5% YoY

EPS (Diluted) -$0.48 +36.8% YoY

Operating Cash Flow -$23.9M +42.8% YoY

Market Cap $372.1M as of Oct 13, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GALT SEC filings page.

This page shows Galectin Therapeutics Inc. (GALT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GALT FY2025 2026-10-03

Galectin remains a development-stage business: lower research spending reduced losses, but liabilities dominate a thin asset base.

Operating loss narrowed to $20.1M in FY2025 as research spending was sharply reduced, indicating the improvement came mainly from spending restraint rather than revenue growth. Yet interest expense rose to $7.3M, leaving net loss at $30.8M; the operating improvement therefore did not translate proportionally to the bottom line.

The balance sheet is structurally strained: FY2025 liabilities were $145.7M against $19.5M of assets, so obligations substantially exceed the resources recorded to support them. Equity was negative at -$127.9M, making asset-based solvency measures less informative than the liability burden itself.

The current ratio rebounded to 2.4x from 0.5x, but that change reflects current liabilities falling rather than a stronger overall balance sheet. Operations consumed $23.9M of cash while financing provided $26.5M, showing that cash needs remained externally funded.

Financial Health Signals

Financial health score not available

Galectin Therapeutics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Galectin Therapeutics Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Galectin Therapeutics Inc. reported a net loss of $30.8M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Galectin Therapeutics Inc. reported an operating loss of $20.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$9.1M

YoY-21.2%

QoQ-80.6%

Galectin Therapeutics Inc. reported -$9.1M in net income in Q2 2026. This represents a decrease of 21.2% from the same quarter a year earlier. Against the prior quarter it is down 80.6%.

EPS (Diluted)

-$0.14

YoY-16.7%

QoQ-75.0%

Galectin Therapeutics Inc. earned -$0.14 per diluted share (EPS) in Q2 2026. This represents a decrease of 16.7% from the same quarter a year earlier. Against the prior quarter it is down 75.0%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$13.3M

YoY-3.6%

QoQ-6.0%

5Y CAGR-15.9%

10Y CAGR-3.0%

Galectin Therapeutics Inc. held $13.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

101M

YoY+57.4%

QoQ+53.1%

5Y CAGR+11.2%

10Y CAGR+13.2%

Galectin Therapeutics Inc. had 101M shares outstanding in Q2 2026. This represents an increase of 57.4% from the same quarter a year earlier. Against the prior quarter it is up 53.1%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending

$2.1M

YoY-34.5%

QoQ-4.3%

Galectin Therapeutics Inc. invested $2.1M in research and development in Q2 2026. This represents a decrease of 34.5% from the same quarter a year earlier. Against the prior quarter it is down 4.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

GALT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GALT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
R&D Expenses	N/A	$14.3M-60.9%	$36.6M+13.8%	$32.1M+1.2%	$31.7M+33.2%	$23.8M+32.5%	$18.0M+140.7%	$7.5M+15.4%	$6.5M-44.8%	$11.7M-23.5%	$15.3M+16.9%	$13.1M+55.7%	$8.4M+48.1%	$5.7M+25.6%	$4.5M+27.4%	$3.6M
SG&A Expenses	N/A	$5.8M-1.1%	$5.9M-1.3%	$5.9M-10.2%	$6.6M+4.0%	$6.4M+16.3%	$5.5M-8.4%	$6.0M-16.3%	$7.1M+57.6%	$4.5M-26.5%	$6.2M-11.6%	$7.0M-0.6%	$7.0M+9.2%	$6.4M+19.4%	$5.4M-21.7%	$6.9M
Operating Income	N/A	-$20.1M+52.7%	-$42.4M-11.5%	-$38.1M+0.7%	-$38.4M-27.1%	-$30.2M-28.7%	-$23.4M-74.5%	-$13.4M+1.2%	-$13.6M+16.3%	-$16.2M+24.4%	-$21.5M-7.0%	-$20.1M-30.1%	-$15.4M-27.5%	-$12.1M-22.3%	-$9.9M+4.9%	-$10.4M
EBITDA	N/A	N/A	-$42.4M-11.5%	-$38.1M+0.7%	-$38.4M-27.1%	-$30.2M-28.7%	-$23.4M-74.5%	-$13.4M+1.2%	-$13.6M+16.3%	-$16.2M+24.3%	-$21.5M-7.0%	-$20.1M-30.2%	-$15.4M-27.5%	-$12.1M-22.3%	-$9.9M+4.9%	-$10.4M
Interest Expense	N/A	$7.3M+32.3%	$5.5M+98.4%	$2.8M+170.3%	$1.0M+111.2%	$489K+462.1%	$87K0.0%	$87K-74.1%	$336K+2700.0%	$12K	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$30.8M+34.5%	-$47.0M-14.6%	-$41.1M-5.9%	-$38.8M-27.0%	-$30.5M-30.1%	-$23.5M-76.5%	-$13.3M+4.4%	-$13.9M+14.4%	-$16.2M+24.3%	-$21.4M-7.0%	-$20.0M-26.8%	-$15.8M-30.6%	-$12.1M-24.9%	-$9.7M+11.4%	-$10.9M
EPS (Basic)	N/A	-$0.48+36.8%	-$0.76-2.7%	-$0.74-13.8%	-$0.65-25.0%	-$0.52-26.8%	-$0.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$0.48+36.8%	-$0.76-2.7%	-$0.74-13.8%	-$0.65-25.0%	-$0.52-26.8%	-$0.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	64M+2.6%	62M+3.6%	60M+1.3%	59M+1.5%	59M+2.6%	57M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$2.1M-34.5%	$2.2M-65.6%	N/A	$2.6M-65.6%	$3.3M-66.8%	$6.5M-19.5%	N/A	$7.6M-1.8%
SG&A Expenses	$1.8M+35.4%	$1.8M+30.7%	N/A	$1.6M+7.9%	$1.4M-7.7%	$1.4M-11.4%	N/A	$1.5M+2.6%
Operating Income	-$4.0M+13.9%	-$4.1M+48.4%	N/A	-$4.2M+53.7%	-$4.6M+59.0%	-$7.9M+18.1%	N/A	-$9.1M+1.1%
Interest Expense	$2.0M+9.7%	$2.0M+14.0%	N/A	$1.8M+21.8%	$1.8M+43.9%	$1.7M+65.8%	N/A	$1.5M+78.9%
Net Income	-$9.1M-21.2%	-$5.0M+47.6%	N/A	-$8.2M+27.1%	-$7.5M+39.2%	-$9.6M+16.2%	N/A	-$11.2M-7.6%
EPS (Basic)	-$0.14-16.7%	-$0.08+46.7%	-$0.08+57.9%	-$0.13+27.8%	-$0.12+40.0%	-$0.15+21.1%	-$0.19-18.8%	-$0.18+25.0%
EPS (Diluted)	-$0.14-16.7%	-$0.08+46.7%	-$0.08+57.9%	-$0.13+27.8%	-$0.12+40.0%	-$0.15+21.1%	-$0.19-18.8%	-$0.18+25.0%
Diluted Shares (Avg)	66M+3.8%	66M+4.1%	N/A	64M+3.1%	63M+2.0%	63M+2.0%	N/A	62M+4.3%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.

GALT Balance Sheet

GALT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$19.5M+11.6%	$17.5M-38.0%	$28.2M+32.5%	$21.3M-49.1%	$41.8M+41.3%	$29.6M-38.9%	$48.5M+438.2%	$9.0M+116.4%	$4.2M-73.7%	$15.8M-40.2%	$26.4M-11.0%	$29.7M+177.0%	$10.7M+12.0%	$9.6M+44.6%	$6.6M
Current Assets	$19.4M+12.7%	$17.3M-37.7%	$27.7M+34.8%	$20.6M-50.9%	$41.8M+41.9%	$29.5M-38.9%	$48.2M+445.8%	$8.8M+131.3%	$3.8M-75.8%	$15.8M-40.2%	$26.4M-11.0%	$29.7M+177.5%	$10.7M+12.3%	$9.5M+46.4%	$6.5M
Cash & Equivalents	$17.7M+17.2%	$15.1M-41.1%	$25.7M+38.0%	$18.6M-53.1%	$39.6M+46.1%	$27.1M-42.8%	$47.5M+475.3%	$8.3M+170.3%	$3.1M-80.1%	$15.4M-40.6%	$25.8M-11.3%	$29.1M+177.7%	$10.5M+12.0%	$9.4M+46.4%	$6.4M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$145.7M+20.9%	$120.6M+36.3%	$88.4M+65.4%	$53.5M+36.4%	$39.2M+625.2%	$5.4M+88.3%	$2.9M+36.2%	$2.1M-55.1%	$4.7M+24.1%	$3.8M-54.8%	$8.4M-1.3%	$8.5M-8.1%	$9.2M+10.0%	$8.4M-3.9%	$8.7M
Current Liabilities	$8.0M-77.3%	$35.4M+125.9%	$15.7M+20.5%	$13.0M+44.0%	$9.0M+67.3%	$5.4M+91.5%	$2.8M+33.8%	$2.1M-29.0%	$3.0M-21.5%	$3.8M+177.9%	$1.4M-20.1%	$1.7M-31.5%	$2.5M+51.8%	$1.6M-26.0%	$2.2M
Non-Current Liabilities	$137.7M+61.7%	$85.2M+17.0%	$72.8M+79.8%	$40.5M+34.1%	$30.2M+377125.0%	$8K-84.6%	$52K	$0-100.0%	$1.7M	$0-100.0%	$7.0M+3.4%	$6.8M+0.5%	$6.7M-0.2%	$6.8M+3.6%	$6.5M
Total Equity	-$127.9M-22.1%	-$104.8M-69.1%	-$62.0M-82.7%	-$33.9M-3898.1%	$893K-96.0%	$22.5M-48.8%	$43.9M+747.8%	$5.2M+1076.4%	-$530K-105.1%	$10.3M-42.9%	$18.0M-14.9%	$21.2M+1331.1%	$1.5M+27.1%	$1.2M+154.8%	-$2.1M
Retained Earnings	-$432.5M-7.7%	-$401.6M-13.3%	-$354.4M-14.5%	-$309.6M-14.4%	-$270.7M-12.8%	-$240.0M-10.9%	-$216.4M-10.3%	-$196.2M-8.3%	-$181.2M-10.7%	-$163.7M-16.9%	-$140.0M-17.8%	-$118.9M-16.6%	-$102.0M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$14.8M-5.0%	$15.8M+65.4%	$19.5M+11.6%	$12.9M-55.6%	$15.6M-43.6%	$9.5M-63.2%	$17.5M-38.0%	$29.0M+30.7%
Current Assets	$14.7M-5.0%	$15.7M+69.0%	$19.4M+12.7%	$12.7M-55.6%	$15.4M-43.5%	$9.3M-63.5%	$17.3M-37.7%	$28.7M+32.6%
Cash & Equivalents	$13.3M-3.6%	$14.1M+89.9%	$17.7M+17.2%	$11.5M-57.4%	$13.8M-46.2%	$7.4M-68.5%	$15.1M-41.1%	$27.1M+32.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$151.7M+14.2%	$146.0M+19.9%	$145.7M+20.9%	$136.4M+12.3%	$132.8M+20.9%	$121.8M+73.3%	$120.6M+36.3%	$121.5M+66.3%
Current Liabilities	$151.6M+1307.3%	$7.3M-93.4%	$8.0M-77.3%	$136.4M+440.2%	$10.8M-26.3%	$110.8M+777.4%	$35.4M+125.9%	$25.3M+140.0%
Non-Current Liabilities	$59K-100.0%	$138.7M+1166.7%	$137.7M+61.7%	$0-100.0%	$122.0M+28.2%	$10.9M-81.0%	$85.2M+17.0%	$96.2M+53.9%
Total Equity	-$138.6M-16.6%	-$132.0M-15.8%	-$127.9M-22.1%	-$125.3M-33.0%	-$118.9M-41.8%	-$114.0M-156.9%	-$104.8M-69.1%	-$94.2M-79.1%
Retained Earnings	-$446.8M-6.7%	-$437.6M-6.4%	-$432.5M-7.7%	-$427.0M-9.6%	-$418.8M-10.7%	-$411.2M-12.4%	-$401.6M-13.3%	-$389.5M-13.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

GALT Cash Flow Statement

GALT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$15.9M	-$23.9M+42.8%	-$41.8M-26.7%	-$33.0M-6.1%	-$31.1M-27.8%	-$24.3M-18.0%	-$20.6M-89.9%	-$10.8M-6.6%	-$10.2M+35.9%	-$15.9M+3.2%	-$16.4M+3.4%	-$17.0M-36.7%	-$12.4M-66.0%	-$7.5M+0.2%	-$7.5M-32.1%	-$5.7M
Depreciation & Amortization	N/A	N/A	$0	$0	$0	$0	$0	$0	$0-100.0%	$1K-85.7%	$7K0.0%	$7K-30.0%	$10K-16.7%	$12K+33.3%	$9K0.0%	$9K
Stock-Based Compensation	N/A	$1.7M-32.2%	$2.4M+8.2%	$2.3M-21.1%	$2.9M+38.1%	$2.1M+15.4%	$1.8M+6.9%	$1.7M-62.1%	$4.4M+303.7%	$1.1M-55.6%	$2.5M-27.1%	$3.4M-16.5%	$4.1M+7.4%	$3.8M+35.7%	$2.8M-14.0%	$3.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0-100.0%	$5K0.0%	$5K
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$17.0M-36.7%	-$12.4M-66.0%	-$7.5M+0.3%	-$7.5M-32.1%	-$5.7M
Investing Cash Flow	N/A	$0	$0	$0	$0	$0	$0	N/A	$0	$0	N/A	N/A	N/A	N/A	$64K+526.7%	-$15K
Financing Cash Flow	$15.4M	$26.5M-15.2%	$31.2M-22.0%	$40.0M+300.3%	$10.0M-72.8%	$36.8M+13897.7%	$263K-99.5%	$50.1M+225.6%	$15.4M+329.2%	$3.6M	N/A	N/A	N/A	$8.6M-17.2%	$10.4M+67.9%	$6.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.4M+63.1%	-$3.9M+49.7%	-$6.0M+52.8%	-$3.5M+58.5%	-$6.6M+20.8%	-$7.7M+36.5%	-$12.8M-172.0%	-$8.5M-11.8%
Stock-Based Compensation	$963K+92.6%	$686K+46.6%	N/A	$498K-3.3%	$500K-32.2%	$468K-22.5%	N/A	$515K-12.1%
Financing Cash Flow	$1.6M-87.7%	$257K	$12.2M+1338.0%	$1.3M-87.0%	$12.9M+24.7%	$0-100.0%	$851K-91.5%	$10.0M-0.3%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

GALT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GALT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Return on Equity	N/A	N/A	N/A	N/A	-3418.5%-3314.1pp	-104.4%-74.1pp	-30.3%+238.3pp	-268.6%	N/A	-208.3%-97.3pp	-111.0%-36.5pp	-74.5%+741.7pp	-816.2%+14.3pp	-830.5%	N/A
Return on Assets	-157.9%+111.1pp	-268.9%-123.3pp	-145.6%+36.6pp	-182.2%-109.2pp	-73.0%+6.3pp	-79.3%-51.8pp	-27.4%+126.9pp	-154.3%+235.8pp	-390.2%-254.5pp	-135.7%-59.9pp	-75.8%-22.6pp	-53.2%+59.6pp	-112.8%-11.6pp	-101.2%+63.9pp	-165.1%
Current Ratio	2.42+1.9x	0.49-1.3x	1.77+0.2x	1.58-3.1x	4.63-0.8x	5.46-11.6x	17.10+12.9x	4.19+2.9x	1.29-2.9x	4.18-15.2x	19.41+2.0x	17.42+13.1x	4.30-1.5x	5.81+2.9x	2.94
Debt-to-Equity	N/A	N/A	N/A	N/A	43.91+43.7x	0.24+0.2x	0.07-0.3x	0.41	N/A	0.37-0.1x	0.46+0.1x	0.40-5.8x	6.23-1.0x	7.21	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Assets	-61.5%-13.3pp	-32.0%+69.1pp	N/A	-63.6%-24.9pp	-48.2%-3.5pp	-101.1%-56.7pp	N/A	-38.7%+8.3pp
Current Ratio	0.10-1.3x	2.15+2.1x	2.42+1.9x	0.09-1.0x	1.43-0.4x	0.08-1.9x	0.49-1.3x	1.13-0.9x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.

Note: Shareholder equity is negative (-$127.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Galectin Therapeutics Inc. GALT	FY2025	N/A	-$30.8M	N/A	$372.1M	—
Autolus Therapeutics plc AUTL	FY2025	$75.4M	-$287.5M	N/A	$463.1M	57/100
DiaMedica Therapeutics Inc. DMAC	FY2025	N/A	-$32.8M	N/A	$442.2M	—
Benitec Biopharma Inc. BNTC	FY2026	N/A	-$45.5M	N/A	$316.4M	—
Larimar Therapeutics, Inc. LRMR	FY2025	N/A	-$165.7M	N/A	$262.8M	—

Where Galectin Therapeutics Inc. Ranks

Frequently Asked Questions

Is Galectin Therapeutics Inc. profitable?

No, Galectin Therapeutics Inc. (GALT) reported a net income of -$30.8M in fiscal year 2025.

What is Galectin Therapeutics Inc.'s operating cash flow?

Galectin Therapeutics Inc. (GALT) recorded an outflow of $23.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Galectin Therapeutics Inc.'s total assets?

Galectin Therapeutics Inc. (GALT) had $19.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Galectin Therapeutics Inc. spend on research and development?

Galectin Therapeutics Inc. (GALT) invested $14.3M in research and development during fiscal year 2025.

How many shares does Galectin Therapeutics Inc. have outstanding?

Galectin Therapeutics Inc. (GALT) had 66M shares outstanding as of fiscal year 2025.

What is Galectin Therapeutics Inc.'s current ratio?

Galectin Therapeutics Inc. (GALT) had a current ratio of 2.42 as of fiscal year 2025, which is generally considered healthy.

What is Galectin Therapeutics Inc.'s return on assets (ROA)?

Galectin Therapeutics Inc. (GALT) had a return on assets of -157.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Galectin Therapeutics Inc.'s P/E ratio?

Galectin Therapeutics Inc. (GALT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $372.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Galectin Therapeutics Inc.'s price-to-sales ratio?

Galectin Therapeutics Inc. (GALT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $372.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Galectin Therapeutics Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Galectin Therapeutics Inc. (GALT) held $17.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.9M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Galectin Therapeutics Inc.'s debt-to-equity ratio negative or not reported?

Galectin Therapeutics Inc. (GALT) has negative shareholder equity of -$127.9M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Galectin Therapeutics Inc.'s Piotroski F-Score?

Galectin Therapeutics Inc. (GALT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Galectin Therapeutics Inc.'s earnings high quality?

Galectin Therapeutics Inc. (GALT) reported a net loss of $30.8M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Galectin Therapeutics Inc. cover its interest payments?

Galectin Therapeutics Inc. (GALT) reported an operating loss of $20.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.